The study appears this month in The Journal of Clinical Investigation, raises a new possibility for potential Alzheimer’s disease treatment: Changes in brain using lipids, a class of fat-soluble compounds that includes cholesterol. It is clear that ABCA1 may a good drug target for Alzheimer’s treatments to be, says Holtzman. There are known drugs that can increase ABCA1, with some further with some further development of this or similar classes of drugs and additional insights into ABCA1 slows down plaque deposition, there may be a way to create a new approach to Alzheimer’s treatment. .
The work showed that ABCA1 facilitates lipidation of HDL and apoE. Holtzman theorizes that this allows apoE intercept better amyloid beta, the main component of the plaques in the brain in a manner that the chances of that form plaques start is reduced. An earlier attempt by other scientists have shown that lipidated apoE binds more strongly to soluble amyloid beta than non – lipidated apoE. But further research is. Prove this theory.On the proven principles of to ELISA innovative feature of microarray array technology the simultaneous multi-analyte testing. At any biochips with 25 DRM Discreet pilot regions . Everyone DTR keeps of a single test. That means that 23 tests found by two of internal quality control antimicrobial agents microarray Array Technology functional are performed without notice.
Randox biochip array bringing on a revolution Clinical Testingbiochips Array Technology Randox is able simultaneous multi analyte diagnostics in the fields of clinical research and trials, Drugs of Abuse Screening and DNA analyzes.